BPC-157 Capsules: Oral Peptide Research and Vendor Picks

BPC-157 capsules are oral formulations of a 15-amino-acid synthetic peptide originally isolated from human gastric juice. The keyword "bpc 157 capsules" draws roughly 3,000 monthly searches in the United States, reflecting growing interest in a needle-free route of administration. All published efficacy data for BPC-157 comes from animal studies. No completed human clinical trial has measured capsule performance, oral bioavailability, or adverse events in people. This page presents the preclinical evidence, compares available products and explains what the research does and does not support.

What Are BPC-157 Capsules?

BPC stands for Body Protection Compound. The peptide sequence GEPPPGKPADDAGLV was first synthesized based on a protein found in human gastric juice by Predrag Sikiric's group at the University of Zagreb. Unlike most peptides, BPC-157 resists degradation in stomach acid, remaining intact at pH 1-2 for over 24 hours in laboratory conditions (Sikiric et al., 2011). That stability makes oral delivery pharmacologically plausible, which is why capsule products exist at all.

Capsule formulations generally consist of freeze-dried BPC-157 powder mixed with other ingredients such as microcrystalline cellulose, rice flour, or magnesium stearate inside a gelatin or vegetarian capsule. Capsule doses range from 200 mcg to 500 mcg. On the other hand, vials contain 5 mg or 10 mg of peptide and require adding bacteriostatic water for injection prior to use.

Why Oral BPC-157 Interests Researchers

The vast majority of therapeutic peptides cannot survive stomach acid. Insulin, growth hormone, and semaglutide (in its injectable form) all require parenteral delivery for this reason. BPC-157's acid stability creates a rare scenario: a bioactive peptide that can contact the gastrointestinal mucosa directly after oral ingestion. In rat models, oral BPC-157 reduced gastric lesion area caused by NSAIDs, ethanol, and restraint stress (Sikiric et al., 1999). Both oral and intraperitoneal routes produced cytoprotective effects, which is unusual for any peptide.

Oral bioavailability is the missing piece of the puzzle. A 2022 pharmacokinetic study in rats and dogs determined systemic absorption rates to be around 2-7% in rats and 3-5% in dogs. These figures are relatively low compared to intramuscular injection's bioavailability (14-19% in rats, 45-51% in dogs). In case of gut-targeted applications, local concentrations may be of more importance than plasma levels, but for systemic targets like muscles or tendons, the bioavailability gap is a concern.

Available BPC-157 Capsule Products

Real Peptides sells BPC-157 capsules: 100 capsules at 500 mcg each for $120. That works out to 50 mg total peptide content. They also sell a 10 mg lyophilized vial at $43.20. PeptideGod does not offer capsules. Their BPC-157 product is a vial priced at $34.95.

How We Rank BPC-157 Products

Items that lack a COA cannot be evaluated in terms of their substance or purity. If there are no third-party test reports, it is impossible to confirm that a particular capsule contains the supposed amount of BPC-157 or whether BPC-157 at all is in a capsule. The same rule applies to both pills and vials.

What Capsules Cannot Tell You

There is no existing data on bioavailability in humans for BPC-157 whether in its capsule form or otherwise. Animal pharmacokinetic data appears to indicate low absorption rates in oral formulations, but those results cannot be used directly with humans. There are additional uncertainties related to products in the form of capsules, including excipient interactions, stability of production through storage, or variability of peptide content from batch to batch. A 2025 formulation review pointed out that although BPC-157 is stable in acid it does not guarantee reliable absorption through oral administration.